Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Investor Day (2025)
11 slides from Orion Oyj Class A's investor day presentation, 2025
Slide 1: Branded Products
Branded Products Hao Pan, Executive Vice President
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Overview of Branded Products Division
Overview of Branded Products Division +9.7% We are building portfolios around key products 77.0 Sales split 70.2 7.2 RESPIRATORY 5.5 9% 23.4 22.1 CNS 30% 60% 42.6 46.5 MEUR WOMEN’S HEALTH Divina® series Q1/2024 Q1/2025 Respiratory CNS Women’s Health 3 Orion CMD 2025 © Orion Corporation
Slide 4: Branded Products Divisional Strategy
Branded Products Divisional Strategy Maximize value of Orion legacy brands and achieve profitable growth Build a customer- • Easyhaler range products for Asthma & COPD Branded Products Divisional Goals driven portfolio: • In-licensed products for respiratory conditions ➢ Easyhaler portfolio has pote
Slide 5: Easyhaler has the right credentials for continued growth
Easyhaler has the right credentials for continued growth Orion Own Sales Countries Respiratory Growth Rates Orion(2024 Ownvs.Sales Countries 2023) Respiratory Growth Rates 2024 (2024 vs. 2023) -2.4% SIMPLE DEVICE TO USE, ACTIVATED BY INHALATION R&D API Via Partner or no active Product manufacturing
Slide 6: Expand offering to all stages of Parkinson's Disease
Expand offering to all stages of Parkinson’s Disease Orion Parkinson’s Disease Current & Future Portfolio UNPREDICTABLE DIAGNOSIS / START OF MEDICATION WEARING-OFF FLUCTUATIONS Early PD Early Stable Wearing-off (WO) Late Stage PD Mild symptoms Non-fluctuating PD Early wearing-off (at least one Sever
Slide 7: Building on Sandrena®/Divigel® Success
Building on Sandrena®/Divigel® Success TRANSDERMAL MENOPAUSE HRT MARKET IS THRIVING TRANSDERMAL MENOPAUSE HRT MARKET IS EXPERIENCING STRONG GROWTH (vol. CARG 2022-2024) ➢ EUROPE 350M€, CAGR +30% ➢ US 650M€, CAGR +30% ➢ ASIA 100M€, CAGR +10% GENERAL MARKET DRIVERS ➢ MARKET RECOVERY: Overcoming WHI st
Slide 8: Leveraging competitive edge with/for our customers
Leveraging competitive edge with/for our customers Therapy area focus with deep knowledge and experience in Parkinson’s Disease Easyhaler / Respiratory inhalation HRT/Divigel ~30 ~35 ~35 years years years European manufacturing and full value chain control Own S&M operations in over API Orion own R&
Slide 9: Branded Products Motto: "Life begins at 30!"
Branded Products Motto: “Life begins at 30!” 9 Orion CMD 2025 © Orion Corporation
Slide 10: Q&A
Q&A 10 Orion CMD 2025 © Orion Corporation
Slide 11: Break
Break Presentations will continue at 14.45 EEST (Finnish time)